Long-term follow-up data on the use of BCMA-directed RNA chimeric antigen receptor T-cell therapy (CAR T) for refractory generalized myasthenia gravis show patient outcomes at 2, 3, 6, 9, and 12 months.

Myasthenia Gravis | Image Credit: © lexiconimages-stock.adobe.com

ADAPT SERON Trial Shows Positive Results for Seronegative gMG

By Marco Meglio

August 28th 2025

Efgartigimod shows promise as a groundbreaking treatment for seronegative generalized myasthenia gravis (gMG), addressing a critical unmet need in patient care.

glucocorticoid | Image Credit: © Vitalii Vodolazskyi-stock.adobe.com

Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation

By Maggie L. Shaw

August 25th 2025

Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.

myasthenia gravis on a chalkboard | Image Credit: © Yurii Kibalnik-stock.adobe.com

MG Symptoms PRO Highlights Rozanolixizumab’s Impact on Fatigue, Weakness

By Maggie L. Shaw

August 22nd 2025

The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan and the European Union following later that year and 2025, respectively.

Myasthenia Gravis | Image Credit: © designua - stock.adobe.com

Nomogram Aids Early Detection of Myasthenic Crisis Risk

By Maggie L. Shaw

August 19th 2025

Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia gravis and being able to predict patients at risk of myasthenic crisis.

...

3 4 5 6 7

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

Do Not Sell My Information

Terms & Conditions